Organization
University of Bologna
3 clinical trials
6 abstracts
Clinical trial
"Multicenter Observational Study to Assess the Incidence and Features of COVID-19 and the Response to COVID-19 Vaccination in Fragile Patients"Status: Active (not recruiting), Estimated PCD: 2023-07-16
Abstract
Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.Org: Niguarda Cancer Center, Laboratory of Experimental Hematology, Clinic of Hematology, Ente Ospedaliero Cantonale, Universita’ della Svizzera italiana,
Clinical trial
International Survey of Acute Coronavirus Syndromes (ISACS)-COVID-19Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)Status: Not yet recruiting, Estimated PCD: 2025-12-31
Abstract
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.Org: MD Anderson Cancer Center, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, University of British Columbia, Institut Curie, Saint Cloud, France, University of Bologna,
Abstract
The lung-immune prognostic index (LIPI) to predict early mortality among patients affected by advanced solid cancers under immune-checkpoint inhibitors treatments.Org: University of Bologna, Medical Oncology Group, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”,
Abstract
Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations.Org: University of Verona, Oncology Section, Verona University Hospital Trust (AOUI Verona), IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia, University of Bologna,
Abstract
ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS IN LARGE-VESSEL VASCULITIDES Org: Medicine and Rheumatology Unit, Rizzoli Orthopaedic Institute, University of Bologna, Laboratory of Immunorheumatology and Tissue Regeneration, Rizzoli Orthopaedic Institute, Bologna, Division Of Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Humanitas Clinical and Research Center, Milano, Italy,
Abstract
AUTOANTIBODIES PROFILE OF RHEUMATOID ARTHRITIS (RA) DURING INFLIXIMAB (INFL) TREATMENTOrg: Medicina Interna Bianchi, Policlinico S. Orsola, University of Bologna, Bologna, Italy,